Clinical Evidence
Explore the science behind our early cancer detection innovations here on our Clinical Evidence page. At Wholomics, transparency and scientific rigor are at the core of what we do. This page is dedicated to showcasing the research and clinical studies that drive our technology forward.
Projects
1. Pancreatic Cancer Projects
Our pancreatic cancer detection project, in collaboration with UMC Amsterdam, marks a significant advancement in identifying this challenging disease in its earliest stages. This project involved a study with 104 participants, carefully balanced between healthy controls and individuals diagnosed with pancreatic cancer, with a focus on early-stage detection. Importantly, the study also included patients with precancerous conditions, providing a comprehensive understanding of the disease's progression.
Key Highlights of the Study:
Participant Demographics: The study comprised 104 individuals, split between healthy controls, pancreatic cancer patients, and patients with chronic pancreatitis.
Focus on Early Detection: Emphasis on identifying pancreatic cancer in its early stages, crucial for effective treatment and outcomes.
Inclusion of Precancerous Conditions: Analysis of patients with precancerous conditions to enhance understanding of early cancer development.
This study represents a critical step in our efforts to improve early detection rates for pancreatic cancer, potentially leading to better patient outcomes and survival rates.
For a detailed insight into our research and findings, we invite you to download the poster we presented at the ASCO GI 2024 conference. This poster encompasses the methodology, results, and implications of our study, highlighting our commitment to combating pancreatic cancer through early detection."
2. Multi Cancer Early Detection Project
Our Multi-Cancer Early Detection (MCED) project is an ambitious initiative that showcases our commitment to revolutionizing cancer diagnosis. This project is a collaboration with seven European Biobanks and involves approximately 4,000 to 5,000 participants. The study is uniquely designed to encompass a broad spectrum of cancers, focusing primarily on early-stage detection.
Key Aspects of the MCED Project:
Broad Collaboration: Engaging with seven European Biobanks, combining diverse data sets and expertise.
Large Scale Participant Pool: The study includes around 4,000 to 5,000 participants, half of whom are healthy controls, while the other half are patients diagnosed with one of 20 different types of cancer.
Focus on Early Stages and Precancerous Conditions: Emphasis on detecting a wide array of cancers in their early stages, including an analysis of precancerous conditions to enhance the understanding of cancer development.
Currently, we are analyzing the first samples. This meticulous process is pivotal in ensuring the accuracy and reliability of our detection methods. Our goal is to complete the study by July 2024, marking a significant milestone in cancer research and early detection efforts.
This MCED project stands as a testament to our dedication to transforming cancer care through early detection, potentially leading to more effective treatment plans and improved survival rates for a wide range of cancers.
We invite researchers, healthcare professionals, and institutions to collaborate with us in this groundbreaking journey. If you're interested in being a part of this transformative project or want more information, please reach out. Together, we can shape the future of cancer care.
3. Monitoring Project:
The Monitoring Project at Wholomics represents a crucial advancement in the ongoing care of cancer patients. Currently in the planning phase, this project has embarked on its first pilot study in collaboration with European Biobanks. The focus is on longitudinal sample collection and analysis from cancer patients, providing valuable insights into the progression and recurrence of the disease.
Key Highlights of the Monitoring Project:
Longitudinal Study Design: Focusing on the collection and analysis of samples over time to monitor cancer progression.
Pilot Study Phase: The initial phase involves a pilot study, currently in the stage of analyzing the first set of samples.
Targeting Unmet Needs in Monitoring: This project aims to offer an effective monitoring solution for patients where traditional tumor markers are either not applicable or lack sufficient accuracy.
The ultimate goal of the Monitoring Project is to provide a more reliable, continuous monitoring system for cancer patients, especially those for whom current methods fall short. This could revolutionize how we track cancer progression and response to treatment, ultimately leading to more personalized and effective care strategies.
We invite collaborations from researchers, healthcare institutions, and biobanks who share our vision of enhancing cancer patient monitoring. If you are interested in participating in this pioneering study or would like more information, please contact us. Your involvement could make a significant difference in the lives of cancer patients worldwide.
4. Therapy Response Prediction:
The Therapy Response Prediction Project at Wholomics is a forward-thinking initiative aimed at enhancing personalized medicine in cancer care. This project, currently in the planning phase, has launched its first pilot study in partnership with European Biobanks. It focuses on developing a methodology to predict how individual patients might respond to common cancer treatments, laying the groundwork for personalized treatment plans and companion diagnostics.
Key Highlights of the Therapy Response Prediction Project:
Pilot Study in Progress: We are in the early stages of this project, currently analyzing the initial set of samples collected.
Personalized Medicine Focus: The project's goal is to develop tools that can predict individual responses to various cancer therapies, enabling more tailored and effective treatment plans.
Companion Diagnostics Development: A significant aim of the project is to create companion diagnostics that can guide therapy choices based on predicted responses.
The objective of this project is to offer a prediction model for therapy responses, which could significantly improve treatment outcomes for cancer patients by personalizing their treatment plans, ultimately steering the future of oncology towards more effective, individualized treatment regimens..
If you would like to contribute to this groundbreaking project or need more information, please reach out to us. Your involvement can help us change the landscape of cancer treatment and improve patient outcomes.
Become a Partner
We invite you to engage directly with us at Wholomics. Whether you're interested in learning more about our groundbreaking projects, exploring potential collaborations, or seeking further information on our pancreatic cancer, MCED, Monitoring, and Therapy Response Prediction initiatives, we're here to connect with you.
Please use the form below to reach out. Your inquiries, insights, and proposals are invaluable to us as we continue to advance the frontiers of early cancer detection and treatment.